Compare
PRO DEX Inc vs Sight Sciences, Inc. vs TELA Bio, Inc. vs Iradimed Corp
| Latest fiscal year | PRO DEX Inc PDEX | Sight Sciences, Inc. SGHT | TELA Bio, Inc. TELA | Iradimed Corp IRMD |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $77.55M | $77.36M | $80.28M | $83.81M |
| Revenue growth (YoY) | +16.5% | -3.1% | +15.8% | +14.4% |
| Gross margin | 31.4% | 86.2% | 67.7% | 76.7% |
| Operating margin | 16.8% | -48.0% | -42.0% | 31.2% |
| Net margin | 17.6% | -49.7% | -48.4% | 26.8% |
| Net income | $13.66M | -$38.43M | -$38.83M | $22.48M |
| EPS (Diluted) | $4.12 | -$0.74 | -$0.83 | $1.75 |
| Operating cash flow | $7.24M | -$29.69M | -$28.22M | $24.95M |
| Free cash flow | $6.76M | -$29.92M | -$28.67M | $17.18M |
| Cash & equivalents | $8.19M | $91.97M | $50.84M | $51.16M |
| Total assets | $74.51M | $115.30M | $81.42M | $108.78M |
| Total liabilities | $26.88M | $51.36M | $75.11M | $14.16M |
| Shareholders' equity | $47.63M | $63.94M | $6.31M | $94.62M |
| Return on year-end equity | 28.7% | -60.1% | -615.1% | 23.8% |
| Shares outstanding | 3.19M | 53.49M | 44.54M | 12.78M |
Revenue, most recent five fiscal years
| Fiscal year | PRO DEX Inc | Sight Sciences, Inc. | TELA Bio, Inc. | Iradimed Corp |
|---|---|---|---|---|
| Latest | $77.55M Ended 2026-06-30 | $77.36M Ended 2025-12-31 | $80.28M Ended 2025-12-31 | $83.81M Ended 2025-12-31 |
| 1 year earlier | $66.59M Ended 2025-06-30 | $79.87M Ended 2024-12-31 | $69.30M Ended 2024-12-31 | $73.24M Ended 2024-12-31 |
| 2 years earlier | $53.84M Ended 2024-06-30 | $81.06M Ended 2023-12-31 | $58.45M Ended 2023-12-31 | $65.56M Ended 2023-12-31 |
| 3 years earlier | $46.09M Ended 2023-06-30 | $71.33M Ended 2022-12-31 | $41.42M Ended 2022-12-31 | $53.30M Ended 2022-12-31 |
| 4 years earlier | $42.04M Ended 2022-06-30 | $48.96M Ended 2021-12-31 | $29.46M Ended 2021-12-31 | $41.81M Ended 2021-12-31 |